Loading
Swissmedic
Swissmedic authorises medicines and devices in Switzerland and Liechtenstein; because Switzerland sits outside the EU it runs its own approvals, but it shares work with the FDA through Project Orbis and the Access Consortium and relies on decisions by comparable regulators.
Also called: Swiss Agency for Therapeutic Products
Overview
Established in 2002, Swissmedic authorises and supervises medicines and medical devices in Switzerland and Liechtenstein. Because Switzerland sits outside the EU, it runs its own approval process, and it has joined international work-sharing through the FDA's Project Orbis, the Access Consortium and reliance procedures for products already approved by comparable regulators. It offers fast-track and temporary authorisation for medicines against serious diseases and regulates the advanced therapies produced by the Swiss pharmaceutical industry. Pricing and reimbursement are decided separately by the Federal Office of Public Health.
Location
Bern, CH
Type
government
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#548 · 6 points (0 Newsweek + 0 NCI + 6 from 3 linked objects) · ranking
Programmes
4- Marketing authorisation and fast-track procedures
- Project Orbis and Access Consortium
- Reliance on foreign approvals
- Market surveillance
People
1Connected
9Similar pages
- IdeaDrop the extra switching studies for interchangeable oncology biosimilars
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- CollectionEMA news and CHMP meeting highlights
Shares European Medicines Agency, FDA Oncology Center of Excellence.
- InstitutionComisión Federal para la Protección contra Riesgos Sanitarios
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- InstitutionBundesinstitut für Arzneimittel und Medizinprodukte
Shares Medicines and Healthcare products Regulatory Agency, European Medicines Agency, Regulatory divergence between regions.
- InstitutionACCELERATE
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- InstitutionPaul-Ehrlich-Institut
Shares European Medicines Agency, Regulatory divergence between regions.
- InstitutionPharmaceuticals and Medical Devices Agency
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- TermICH good clinical practice (E6)
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
swissmedic.ch · 1
A source that has moved or gone is reported by the weekly link check. /audit/